A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects With Primary Biliary Cirrhosis Who Had an Inadequate Response to Ursodeoxycholic Acid (UDCA)

Trial Profile

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects With Primary Biliary Cirrhosis Who Had an Inadequate Response to Ursodeoxycholic Acid (UDCA)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PURIFI
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Nov 2015 Results published in the Hepatology
    • 29 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top